4-(5-Fluoropyridin-2-yl)-2azetidinones to Fight Against Drug-Resistant Pancreatic Cancer

The University of Texas Rio Grande Valley Background
Around 95% of pancreatic tumors are driven by mutations in KRAS gene, subbed “undruggable” and prevalent in 5 drug-resistant pancreatic cancers. Currently, there is no effective medicine in the market for drug-resistant cancers.
Technology Overview
The present technology consists of compounds that demonstrate outstanding results against drug-resistant cancer cell lines.
6 potent anti-pancreatic cancer 2-azetidinone molecules against drug-resistant cell lines were designed, validated in silico, synthesized through multi-step process, and conducted in vitro anti-pancreatic cancer evaluation (2D-culture & 3D-tumorsphere formation assays). The series consists of 12 small molecules ().
Stage of Development
A prototype is near commercial grade, and has been tested in an operational lab environment.
Benefits

3 to 359 times more selective towards PANC-1 cells compared to normal pancreatic ductal epithelial cells
Potential antibacterial and drug-resistant antibacterial activity against various types of infections

Value Proposition
These derivatives of compounds show excellent cytotoxicity against drug-resistant pancreatic cancer cell lines (PANC-1 cells): Best IC50 values in 2D-culture and 3D-tumorsphere assays are 2.55 nM and 2.33 nM, respectively.

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More